This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Quaresima, B. Articles by Costanzo, F. Search for Related Content PubMed PubMed Citation Articles by Quaresima, B. Articles by Costanzo, F.

BRCA1 5083del19 Mutant Allele Selectively Up-Regulates Periostin Expression In vitro and In vivo

Authors' Affiliations: ¹ Department of Experimental and Clinical Medicine, "Magna Græcia" University of Catanzaro; ² Azienda Ospedaliera "Pugliese-Ciaccio" of Catanzaro, Catanzaro, Italy, and ³ Comprehensive Cancer Center, Ohio State University, Columbus, Ohio

Requests for reprints: Francesco Costanzo, Department of Experimental and Clinical Medicine, "Magna Græcia" University of Catanzaro, "Salvatore Venuta" Campus, Viale Europa, 88100 Catanzaro, Italy. Phone: 39-961-3694097; Fax: 39-961-3694112; E-mail: fsc{at}unicz.it.

Purpose: The aim of this study was to explore the gene expression pattern produced by the cancer-associated BRCA1 5083del19 founder mutation by using a microarray analysis. Such a mutation, identified in a subset of familial breast cancer patients, involves a deletion at the 3' end of the BRCA1 messenger leading, in the mature protein, to the ablation of the BRCT tandem domain.

Experimental Design: We generated HeLa cells stably expressing both exogenous wild-type (HeLa/^wtBRCA1), used as a control, and 5083del19 BRCA1 (HeLa/^5083del19BRCA1) alleles; gene chips were then used to investigate any changes in the transcription profile induced by the 5083del19 BRCA1 mutant compared with controls.

Results: Among the genes showing perturbation of their expression, periostin was found to be up-regulated in HeLa/^5083del19BRCA1 cells to an extent of 72-fold versus HeLa/^{pcDNA3.1/empty} and 76-fold versus HeLa/^wtBRCA1 cells. This finding was validated both in vitro in breast cancer cell lines harboring mutations of BRCA1 and in vivo by immunohistochemistry of breast cancer specimens bearing the 5083del19 BRCA1 mutation as well as by Western blot analysis of sera obtained from patients and healthy carriers of the same mutation.

Conclusions: Our results suggest that periostin overexpression, whose product is released from cells in the extracellular fluids, might be a potential marker for early cancer detection in a specific subset of hereditary breast carcinomas triggered by cancer-associated BRCA1 mutations that affect the BRCT tandem domain.